Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer

NCT ID: NCT04262635

Last Updated: 2023-08-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-24
• Study Completion Date: 2024-08-30

Brief Summary

This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without discontinuation for toxicity, of cetuximab or fluorouracil or oxaliplatin,, and achieved disease control (including CR/PR and SD), and are progression free at the end of Cycle 9 will be assigned to 2 maintenance treatment groups by randomization in a 1:1 ratio to receive cetuximab + capecitabine (Arm A) or cetuximab alone (Arm B). The randomization will be stratified by induction treatment response (complete response [CR]+ partial response [PR] versus stable disease [SD]) and primary tumor location (left side only versus right side). All patients from Arm A and Arm B will be treated until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal (whichever occurs earlier).

Detailed Description

Coz COVID-19 limited, C-CLASSIC was terminated recruitment on 31Dec2022. Total screen 100 subjects and enroll 80 subjects. All subjects in study will be treatment until meet study endpoint. Then study related subject follow up, data collect, clinical study report will be continued as planned.

Conditions

Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ArmA Cetuximab plus Capecitabine

Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W); plus capecitabine in 2-week cycles until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal

Group Type: EXPERIMENTAL

Cetuximab, Capecitabine

Intervention Type: DRUG

Maintenance treatment ( ArmA )

ArmB Cetuximab

Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W) until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal

Group Type: ACTIVE_COMPARATOR

Cetuximab

Intervention Type: DRUG

Maintenance treatment ( ArmB )

Interventions

Cetuximab, Capecitabine

Maintenance treatment ( ArmA )

Intervention Type: DRUG

Cetuximab

Maintenance treatment ( ArmB )

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written informed consent prior to performance of any study procedure.

2. Patient must be ≥18 years of age, at the time of signing the informed consent.

3. Patients who have histologically or cytologically confirmed adenocarcinoma of the colon or rectum, excluding appendix carcinoma or anal canal carcinoma, with RAS and BRAF wild-type mutation status.

4. Patients who received only FOLFOX plus cetuximab as first-line induction treatment after diagnosis of mCRC.

5. Having completed FOLFOX plus cetuximab for 9 cycles as induction treatment (in the first cycle, they could be treated with FOLFOX alone for waiting the results of genetic test) without discontinuation for toxicity, of cetuximab or fluorouracil or oxaliplatin and achieved disease control (including CR/PR and SD) and are progression free at the start of maintenance therapy.

6. At least one lesion(s), which is considered as unresectable at start of maintenance therapy (mCRC patients with resectable lesion(s) after induction treatment can be enrolled if they are willing to choose maintenance therapy). Patients who achieved CR and had no measurable lesion after induction treatment can be enrolled in this study.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

8. Life expectancy of at least 12 weeks in the opinion of the investigator.

9. Laboratory requirements

• Neutrophils ≥1.5×109/L, platelets ≥75×109/L, and hemoglobin ≥9 g/dL;
• Total bilirubin ≤1.5×upper limit of normal (ULN); aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and/or alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT)

• 2.5×ULN (≤5×ULN in case of liver metastases); alkaline phosphatase
• 2.5×ULN (≤5×ULN in case of liver metastases, ≤10×ULN in case of bone metastases); lactate dehydrogenase (LDH) <1500 U/L;
• Creatinine clearance (calculated according to Cockcroft and Gault) >60 mL/min or serum creatinine ≤1.5×ULN.

Exclusion Criteria

1. Having received chemotherapy for mCRC other than induction therapy with FOLFOX plus cetuximab, except for adjuvant therapy that has ended >9 months (oxaliplatin- based chemotherapy) or >6 months (oxaliplatin-free chemotherapy), prior to the start of the induction treatment.

2. Other concurrently active malignancies, excluding malignancies that are disease free for more than 5 years or carcinoma-in-situ deemed cured by adequate treatment. Patients who are definitely detected as dMMR/MSI-H at the start of induction therapy.

3. Known brain metastasis or leptomeningeal metastasis. Patients with neurological symptoms should undergo brain computed tomography (CT)/ magnetic resonance imaging (MRI) to exclude metastases.

4. Unresolved toxicity greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation). Patients with platinum induced neurotoxicity greater than or equal to CTCAE Grade 3 should be excluded.

5. Ascites, pleural effusion or pericardial fluid requiring drainage in last 4 weeks.

6. Intestinal obstruction, major gastrointestinal hemorrhage or other diseases not suitable for maintenance treatment in this study as assessed by the investigator within 2 weeks prior to enrollment.

7. Diabetes and hypertension as assessed by the investigator as not eligible for the subsequent maintenance treatment in this study.

8. Myocardial infarction within the last 12 months, severe/unstable angina, symptoms of class III or IV congestive heart failure per New York Heart Association (NYHA) classification.

9. Previous hypersensitivity to any of the study drugs (cetuximab or capecitabine).

10. Deficiency in dihydropyrimidine dehydrogenase (DPD) as manifested by known medical history of fluorouracil adverse reactions.

11. Known infection with human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS)-related illness, or active hepatitis B (positive HBsAg and HBV-DNA ≥ 2000 IU/mL or 104 copies/mL) or hepatitis C. Patients with previously confirmed COVID-19 infection, including severe, mild, asymptomatic, and recovered patients.

12. Patients with active autoimmune disorders requiring treatment or history of organ transplantation requiring immunosuppressive therapy.

13. Psychiatric disease that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results.

14. Treatment with any of the following within the specified time frame prior to study drug administration

• Major surgery within 4 weeks (excluding diagnostic biopsy, the surgical incision should be fully healed prior to study drug administration);
• Radiotherapy within 4 weeks;
• Anti-cancer therapy other than protocol-specified induction therapy or participation in other clinical studies within 4 weeks.
• Anti-tumor traditional Chinese medicine within 2 weeks (such as Cantharidin, Cinobufacini).

15. Pregnant (as determined by serum human chorionic gonadotropin [hCG] test) or lactating female, or female planning to become pregnant during treatment and for 2 months after the end of treatment with cetuximab and 6 months after the end of capecitabine. Woman of childbearing potential (WOCBP) with either positive or no pregnancy test at baseline. WOCBP or sexually active men not willing to use contraception during study and for at least 3 months after completion of cetuximab and 6 months after completion of capecitabine. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.

16. Presence of other serious disease or social circumstances that precludes patient enrollment in the opinion of the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Rui-hua Xu, MD, PhD

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ruihua Xu, MD

Role: STUDY_CHAIR

Sun Yat-sen University

Locations

Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, China

Countries

China

Other Identifiers

C-CLASSIC

Identifier Type: -

Identifier Source: org_study_id